CPRX - CIK 0001369568
CATALYST PHARMACEUTICALS, INC. trades as CPRX and has a market capitalization of $3.84 B, making it the #1606 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $588.99M, up 19.8% from the prior year and net income of $214.33M. This page tracks CATALYST PHARMACEUTICALS, INC. through 1,337 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin expanded from -6800.7% to 36.4% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Proxy materials | DEFA14A | 2026-05-12 |
| Quarterly report | 10-Q | 2026-05-11 |
| Major company event | 8-K | 2026-05-11 |
| Proxy materials | DEFA14A | 2026-05-08 |
| Proxy materials | DEFA14A | 2026-05-07 |
| Proxy materials | DEFA14A | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Annual report (amended) | 10-K/A | 2026-04-30 |
_Delivered Q1 2026 Total Revenues_ _of $149.4 Million_
_As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035_
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., has been recognized by Forbes as one of America’s Most Successful Company in 2023, 2024, and 2025, and on the 2025 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.
The webcast will be accessible under the Investors section on the Company's website at www.catalystpharma.com. A webcast replay will be available on Catalyst’s website for at least 30 days following the date of the event.
The largest companies sharing CATALYST PHARMACEUTICALS, INC.'s SEC industry classification (pharmaceutical preparations).
CATALYST PHARMACEUTICALS, INC. (CPRX) has a market capitalization of $3.84 B as of 2026-06-10, ranking #1606 among US-listed companies.
CATALYST PHARMACEUTICALS, INC. reported revenue of $588.99M for fiscal year 2025, an increase of 19.8% year over year.
Yes. CATALYST PHARMACEUTICALS, INC. reported net income of $214.33M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
“The MDA meeting is a key opportunity to highlight the expanding real‑world evidence shaping care for the Duchenne community,” said Will Andrews, MD, Chief Medical Officer of Catalyst. “Through our poster presentations and our sponsored symposium on long‑term evidence generation, we’re contributing clinical insights that help clarify AGAMREE®’s profile and its role in patient care. Our commitment is to advance rigorous, meaningful research that moves the field forward for patients and their families.”